Abstract
Pustular psoriasis (PP) encompasses a range of well-defined, severe inflammatory conditions characterized by production of sterile pustules. Our understanding of this rare disease’s pathophysiology, clinical course and optimal treatment is as yet limited. The goal of this prospective international registry is to describe the natural course of disease in different subtypes of PP and create phenotype-genotype correlations as well as elucidate therapeutic molecular pathways. The IRASPEN registry plans to include at least 180 patients at approximately 15 sites world-wide, aiming for minimum numbers of 140 Palmoplantar Psoriasis (PPP), 20 Generalized Pustular Psoriasis (GPP) and 20 Acrodermatitis Continua of Hallopeau (ACH) patients and up to 360 non-affected first degree relatives.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
